Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited

TORNTPHARM

Classement en actions #1189
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Prix de l'action
$50.16
Capitalisation boursière
$19.08B
Changement (1 jour)
-0.30%
Changement (1 an)
22.94%
Pays
IN
Échange Torrent Pharmaceuticals Limited (TORNTPHARM)

Catégorie

Healthcare
Revenus pour Torrent Pharmaceuticals Limited (TORNTPHARM)
Revenus en Jun 2026 TTM : $1.72B
Selon les derniers rapports financiers de Torrent Pharmaceuticals Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $1.72B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $1.29B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $1.17B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Torrent Pharmaceuticals Limited de 2005 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $1.72B 27.98%
2025 $1.35B 4.66%
2024 $1.29B 9.91%
2023 $1.17B 4.44%
2022 $1.12B 2.50%
2021 $1.09B 3.76%
2020 $1.05B -4.62%
2019 $1.10B 20.92%
2018 $913.81M 1.90%
2017 $896.80M -10.88%
2016 $1.01B 34.94%
2015 $745.76M -3.94%
2014 $776.35M 31.37%
2013 $590.99M 15.51%
2012 $511.64M 7.45%
2011 $476.15M 11.61%
2010 $426.62M 32.82%
2009 $321.20M -5.13%
2008 $338.57M 13.00%
2007 $299.62M 37.98%
2006 $217.15M 73.11%
2005 $125.44M 0.00%
Revenus d’entreprises similaires ou concurrentes